Related Experiment Videos
Protection against experimental autoimmune encephalomyelitis by a proteasome modulator
H Hosseini1, P André, N Lefevre
1INSERM U421, Faculté de Médecine 8, rue du général Sarrail, 94010 cedex, Créteil, France.
Journal of Neuroimmunology
|August 11, 2001
Summary
Ritonavir, an HIV-1 protease inhibitor, shows therapeutic potential for multiple sclerosis by modulating proteasome function. This drug prevented symptoms in an experimental model, suggesting a new approach for autoimmune diseases.
Area of Science:
- Immunology
- Neuroscience
- Pharmacology
Background:
- Interferon beta's success in multiple sclerosis (MS) highlights immune modulation over suppression.
- The proteasome is vital for immune cell survival and inflammatory control, making it a therapeutic target for autoimmune diseases.
Purpose of the Study:
- To explore the therapeutic potential of ritonavir, an HIV-1 protease inhibitor, in experimental autoimmune encephalomyelitis (EAE), a model for MS.
- To investigate ritonavir's effects on proteasome function and its implications for autoimmune disease treatment.
Main Methods:
- Administered ritonavir daily to Lewis rats and SJL mice during autoimmune antigen stimulation.
- Assessed clinical symptoms of EAE, mononuclear cell infiltration into the central nervous system, and resistance to further EAE induction.
Main Results:
- Daily ritonavir administration prevented EAE clinical symptoms in a dose- and time-dependent manner.
- Protection correlated with inhibited mononuclear cell infiltration into the central nervous system.
- Ritonavir-treated animals developed resistance to subsequent EAE induction, suggesting immune-based protection.
Conclusions:
- Proteasome modulation via ritonavir or similar drugs may offer a novel therapeutic strategy for multiple sclerosis.
- Ritonavir's ability to prevent EAE and induce resistance suggests a promising role in managing autoimmune conditions.